This pilot study is the first proof-of-principle attempt to predict treatment response and/or survival outcome among melanoma patients -- based on their Nodal expression profile relevant to anti-PD1 immune checkpoint inhibitor therapy. The gene discussed is PDCD1; the disease is melanoma.